Utah Medical Products (UTMD) Common Equity (2010 - 2026)

Utah Medical Products' Common Equity history runs 17 years deep, the most recent figure standing at $120.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 2.84% year-over-year to $120.4 million in Q1 2026; TTM through Mar 2026 was $120.4 million, a 2.84% increase from a year earlier, with the FY2025 full-year figure at $119.3 million, up 1.57% from the prior year.
• Common Equity advanced to $120.4 million in Q1 2026 per UTMD's latest filing, from $119.3 million in the prior quarter.
• Across five years, Common Equity topped out at $128.3 million in Q4 2023 and bottomed at $107.5 million in Q2 2022.
• The 5-year median for Common Equity is $118.3 million (2025), against an average of $118.6 million.
• Across the five-year window, Common Equity increased 14.34% in 2023 and decreased 8.48% in 2024, its largest moves.
• Year by year, Common Equity stood at $114.3 million in 2022, then climbed by 12.3% to $128.3 million in 2023, then dropped by 8.48% to $117.4 million in 2024, then advanced by 1.57% to $119.3 million in 2025, then grew by 0.93% to $120.4 million in 2026.
• Per Business Quant, the three latest UTMD Common Equity figures stand at $120.4 million (Q1 2026), $119.3 million (Q4 2025), and $118.3 million (Q3 2025).